- Home
- TARA vs SRV Comparison
TARA vs SRV Comparison
Compare TARA & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARA | SRV |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 225.9M |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TARA | SRV |
|---|---|---|
| Price | $3.97 | $45.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $24.40 | N/A |
| AVG Volume (30 Days) | ★ 337.6K | 53.9K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $38.11 |
| 52 Week High | $7.82 | $51.54 |
Technical Indicators
Market Signals| Indicator | TARA | SRV |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 36.31 |
| Support Level | $3.73 | $43.83 |
| Resistance Level | $4.17 | $46.19 |
| Average True Range (ATR) | 0.14 | 0.99 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 59.78 | 4.49 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end investment company. Its investment objective is to obtain a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in a portfolio of midstream energy investments.